NEW YORK (GenomeWeb News) – MD Anderson Cancer Center has expanded its license agreement with bioinformatics company BioDiscovery for the Nexus Copy Number microarray software platform, the company said today.
 
The software is used to analyze and visualize chromosomal aberrations from microarray data, and the agreement allows many users in different labs to use it at the same time. MD Anderson expanded the original site license agreement to enterprise level, BioDiscovery said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.